Posted by Michael Wonder on 10 Apr 2025
PHARMAC to fund medicines for blood cancers, inflammatory bowel disease, eczema and arthritis
10 April 2025 - More New Zealanders will have access to medicines for blood cancers, bowel diseases, eczema and arthritis, following PHARMAC’s decision to widen access to four medicines for six health conditions from 1 May 2025.
The medicines are:
- Venetoclax (Venclexta) in combination with azacitidine or cytarabine for acute myeloid leukaemia
- Azacitidine (Azacitidine Dr Reddy’s) for acute myeloid leukaemia
- Ibrutinib (Imbruvica) for chronic lymphocytic leukaemia
- Upadacitinib monohydrate (Rinvoq) for atopic dermatitis, ulcerative colitis, Crohn disease and rheumatoid arthritis
